Banking Earnings Report | 2026-05-05 | Quality Score: 94/100
We deliver daily stock analysis focused on earnings performance, price trends, and institutional activity, helping users track market opportunities across major US-listed companies.
This analysis evaluates the upcoming Q1 2026 earnings release for Tempus AI (NASDAQ: TEM), the AI-powered diagnostics stock that previously rallied on Nancy Pelosi’s 2025 position disclosure, as investors weigh whether fundamental improvements can reverse its 50% pullback from 2025 peaks and narrow
Live News
As of market close on May 4, 2026, implied volatility for Tempus AI (TEM) front-month at-the-money options is priced at 42%, reflecting elevated investor uncertainty ahead of its Q1 2026 earnings release scheduled for after trading hours on May 5. TEM first gained widespread retail and institutional attention in January 2025, following a mandatory public disclosure of a personal position in the stock by former U.S. House Speaker Nancy Pelosi, whose long-running market-beating trading track recor
Invesco QQQ Trust (QQQ) - Tempus AI (TEM) Q1 2026 Earnings Preview: Can Operational Progress Revive Post-Pullback Momentum?Global macro trends can influence seemingly unrelated markets. Awareness of these trends allows traders to anticipate indirect effects and adjust their positions accordingly.Diversification in analysis methods can reduce the risk of error. Using multiple perspectives improves reliability.Invesco QQQ Trust (QQQ) - Tempus AI (TEM) Q1 2026 Earnings Preview: Can Operational Progress Revive Post-Pullback Momentum?Timely access to news and data allows traders to respond to sudden developments. Whether it’s earnings releases, regulatory announcements, or macroeconomic reports, the speed of information can significantly impact investment outcomes.
Key Highlights
First, 2025 fourth-quarter results established a critical foundational benchmark for 2026 performance: TEM reported 83% year-over-year (YoY) revenue growth to $367.21 million, with its high-margin Diagnostics segment surging 121.6% YoY, and adjusted EBITDA turning positive for the first time at $12.89 million, a sharp improvement from a $1.48 million adjusted EBITDA loss in Q3 2025. Second, no consensus EPS or revenue estimates are available for Q1 2026 in available datasets, making management’s
Invesco QQQ Trust (QQQ) - Tempus AI (TEM) Q1 2026 Earnings Preview: Can Operational Progress Revive Post-Pullback Momentum?Scenario planning prepares investors for unexpected volatility. Multiple potential outcomes allow for preemptive adjustments.Traders often combine multiple technical indicators for confirmation. Alignment among metrics reduces the likelihood of false signals.Invesco QQQ Trust (QQQ) - Tempus AI (TEM) Q1 2026 Earnings Preview: Can Operational Progress Revive Post-Pullback Momentum?Market participants frequently adjust their analytical approach based on changing conditions. Flexibility is often essential in dynamic environments.
Expert Insights
The “Pelosi halo” premium that once lifted TEM to triple-digit valuations has fully unwound, with investors now prioritizing durable, profitable growth over meme-style trading catalysts, a shift that aligns with broader 2026 market sentiment favoring profitability in high-growth AI names relative to unprofitable cash burners. First, adjusted EBITDA sustainability is the most critical near-term catalyst. Q4 2025 marked the first quarter of positive adjusted EBITDA for TEM, and a second consecutive positive print would validate management’s ability to hit its full-year 2026 adjusted EBITDA target of $65 million, a milestone that would justify a valuation re-rating relative to its unprofitable healthcare AI peers, which currently trade at an average 6.2x forward revenue multiple, compared to TEM’s current 4.8x 2026 estimated revenue multiple. A return to adjusted EBITDA losses would invalidate the core bullish recovery thesis, likely triggering a 15% to 20% near-term pullback. Second, the Insights segment’s 40% guided Q1 growth target, paired with a 126% net revenue retention (NRR) rate and $1.1 billion total contract value (TCV) forecast, will serve as a key read on underlying pharma demand for TEM’s proprietary real-world clinical data assets. Any outperformance here, particularly from new customer additions rather than one-time contract adjustments, would confirm the company’s moat in the fast-growing precision medicine data space, while a miss would signal cooling demand for its data services. Third, MRD test volume growth is the primary long-term upside catalyst. TEM ran 4,700 MRD tests in Q4 2025, up 56% sequentially, with only 5% of its sales force currently focused on selling the product, implying massive untapped penetration potential. An acceleration in MRD volumes would signal that the product is gaining mainstream clinical adoption, which could drive a step-change in revenue growth over the next 24 months. It is important to note that even a narrow beat on guidance may not be enough to drive sustained upside, as investors have already priced in a modest recovery following the 16.95% rally over the past month. Conversely, a cross-the-board beat with upward full-year guidance revisions could drive a 25% to 30% rally, reigniting institutional inflows and narrowing TEM’s wide performance gap with the QQQ. (Word count: 1172)
Invesco QQQ Trust (QQQ) - Tempus AI (TEM) Q1 2026 Earnings Preview: Can Operational Progress Revive Post-Pullback Momentum?Market participants often refine their approach over time. Experience teaches them which indicators are most reliable for their style.Real-time tracking of futures markets often serves as an early indicator for equities. Futures prices typically adjust rapidly to news, providing traders with clues about potential moves in the underlying stocks or indices.Invesco QQQ Trust (QQQ) - Tempus AI (TEM) Q1 2026 Earnings Preview: Can Operational Progress Revive Post-Pullback Momentum?Monitoring commodity prices can provide insight into sector performance. For example, changes in energy costs may impact industrial companies.
